Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Contribution of CD95 ligand-induced neutrophil infiltration to the bystander effect in p53 gene therapy for human cancer.

Waku T, Fujiwara T, Shao J, Itoshima T, Murakami T, Kataoka M, Gomi S, Roth JA, Tanaka N.

J Immunol. 2000 Nov 15;165(10):5884-90.

2.

Recombinant adenovirus expressing wild-type p53 is antiangiogenic: a proposed mechanism for bystander effect.

Nishizaki M, Fujiwara T, Tanida T, Hizuta A, Nishimori H, Tokino T, Nakamura Y, Bouvet M, Roth JA, Tanaka N.

Clin Cancer Res. 1999 May;5(5):1015-23.

3.

Differential involvement of the CD95 (Fas/APO-1) receptor/ligand system on apoptosis induced by the wild-type p53 gene transfer in human cancer cells.

Fukazawa T, Fujiwara T, Morimoto Y, Shao J, Nishizaki M, Kadowaki Y, Hizuta A, Owen-Schaub LB, Roth JA, Tanaka N.

Oncogene. 1999 Apr 1;18(13):2189-99.

4.

Transduction of dendritic cells with Bcl-xL increases their resistance to prostate cancer-induced apoptosis and antitumor effect in mice.

Pirtskhalaishvili G, Shurin GV, Gambotto A, Esche C, Wahl M, Yurkovetsky ZR, Robbins PD, Shurin MR.

J Immunol. 2000 Aug 15;165(4):1956-64.

5.

CD95 ligand-expressing tumors are rejected in anti-tumor TCR transgenic perforin knockout mice.

Behrens CK, Igney FH, Arnold B, Möller P, Krammer PH.

J Immunol. 2001 Mar 1;166(5):3240-7.

7.

Chimeric tumor suppressor 1, a p53-derived chimeric tumor suppressor gene, kills p53 mutant and p53 wild-type glioma cells in synergy with irradiation and CD95 ligand.

Naumann U, Kügler S, Wolburg H, Wick W, Rascher G, Schulz JB, Conseiller E, Bähr M, Weller M.

Cancer Res. 2001 Aug 1;61(15):5833-42.

8.

Adenovirus-mediated p53 gene therapy inhibits human sarcoma tumorigenicity.

Milas M, Yu D, Lang A, Ge T, Feig B, El-Naggar AK, Pollock RE.

Cancer Gene Ther. 2000 Mar;7(3):422-9.

9.

Fas ligand on tumor cells mediates inactivation of neutrophils.

Chen YL, Chen SH, Wang JY, Yang BC.

J Immunol. 2003 Aug 1;171(3):1183-91.

10.

Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein.

Harris MP, Sutjipto S, Wills KN, Hancock W, Cornell D, Johnson DE, Gregory RJ, Shepard HM, Maneval DC.

Cancer Gene Ther. 1996 Mar-Apr;3(2):121-30.

PMID:
8729911
11.

E2F-1 overexpression sensitizes colorectal cancer cells to camptothecin.

Dong YB, Yang HL, McMasters KM.

Cancer Gene Ther. 2003 Mar;10(3):168-78.

PMID:
12637937
12.

The role of natural killer cells in adenovirus-mediated p53 gene therapy.

Carroll JL, Nielsen LL, Pruett SB, Mathis JM.

Mol Cancer Ther. 2001 Nov;1(1):49-60.

13.

Canarypox virus expressing wild type p53 for gene therapy in murine tumors mutated in p53.

Odin L, Favrot M, Poujol D, Michot JP, Moingeon P, Tartaglia J, Puisieux I.

Cancer Gene Ther. 2001 Feb;8(2):87-98.

14.

In vivo adenovirus-mediated p53 tumor suppressor gene therapy for colorectal cancer.

Spitz FR, Nguyen D, Skibber JM, Cusack J, Roth JA, Cristiano RJ.

Anticancer Res. 1996 Nov-Dec;16(6B):3415-22.

PMID:
9042200
15.
17.

Dendritic cells transduced with wild-type p53 gene elicit potent anti-tumour immune responses.

Ishida T, Chada S, Stipanov M, Nadaf S, Ciernik FI, Gabrilovich DI, Carbone DP.

Clin Exp Immunol. 1999 Aug;117(2):244-51.

18.

Effective gene-virotherapy for complete eradication of tumor mediated by the combination of hTRAIL (TNFSF10) and plasminogen k5.

Liu XY, Qiu SB, Zou WG, Pei ZF, Gu JF, Luo CX, Ruan HM, Chen Y, Qi YP, Qian C.

Mol Ther. 2005 Apr;11(4):531-41.

PMID:
15771956
20.

Differential activation of the Fas/CD95 pathway by Ad-p53 in human gliomas.

Cerrato JA, Khan T, Koul D, Lang FF, Conrad CA, Yung WK, Liu TJ.

Int J Oncol. 2004 Feb;24(2):409-17.

PMID:
14719118
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk